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Background: Fluoropyrimidines are generally well tolerated drugs, but can result in
severe, potentially fatal toxicity in up to 30% of patients. Themajor cause of toxicity is
reduced activity of the key metabolizing enzyme dihydropyrimidine dehydrogenase
(DPD), most often the result of genetic DPYD variants. In this prospective clinical trial
we determined whether toxicity of fluoropyrimidine treatment can be reduced by
upfront screening for 4 relevant DPYD variants and DPYD genotype-guided dosing.
Methods: Prospective genotyping for DPYD*2A, c.2846A>T, c.1679T>G and
c.1236G>Awas performed in patients prior to start of fluoropyrimidine-based ther-
apy. Heterozygous DPYD variant carriers received an initial dose reduction of 25%
(c.2846A>T, c.1236G>A) or 50% (DPYD*2A, c.1679T>G). Incidence of severe (grade
3) toxicity in DPYD variant carriers was compared to a historical cohort of DPYD
variant carriers treated with full dose.
Results:A total of 1,103 evaluable patients was enrolled, of whom 85 were heterozygous
DPYD variant carriers (7.7%). In DPYD variant carriers the overall frequency of grade
3 toxicity was 39%.When comparing to the historical cohort, DPYD genotype-
guided dosingmarkedly reduced the risk of grade3 toxicity for DPYD*2A and
c.1679T>G carriers, moderately reduced risk for c.2846A>T carriers, and resulted in a
similar risk for c.1236G>A carriers. Pharmacokinetic analyses showed that fluoropyri-
midine exposure after dose reductions in DPYD variant carriers was comparable to
wild-type patients. A cost-analysis showed that the reduced risk in toxicity resulted in
average total treatments costs per patient that were even lower for the screening strategy
(f2599) compared to non-screening (f2650).
Conclusions:Upfront DPYD genotyping improves patient safety during fluoropyrimi-
dine chemotherapy, is feasible in routine practice, and is cost saving. For heterozygous
DPYD*2A and c.1679T>G carriers, a 50% initial dose reduction is recommended. For
c.1236G>A and c.2846A>T carriers the applied dose reductions of 25% in this study
were not enough to lower the risk of severe toxicity in this group, so more cautious
dose reductions of 50% are recommended.
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Background: This trial evaluated activity and safety of mFOLFOXIRIþ panitumumab
vs FOLFOXIRI in ECOG 0-1, primarily non-resectable mCRC patients.
Methods: Prospective 2:1 randomized, multi-center, phase II trial comparing
mFOLFOXIRI (Ox 85, Iri 150, 5-FU 3000, LV 200)þ Panitumumab 6mg/KG (arm A)
with FOLFOXIRI (Ox 85, Iri 165, 5-FU 3200 cont. 48h, LV 200; arm B). Cohort 1: irre-
sectable mCRC; cohort 2: chance of secondary resection of metastatic lesions. Primary
endpoint: ORR, secondary endpoints: secondary resection rate, DCR, PFS, OS, toxicity,
QL (QLQ-C30). Financially supported by an unrestricted grant from Amgen.
Results:A total of 96 patients were randomized (63 arm A, 33 arm B). After an observa-
tion time of 29months in both arms, final ORR results are displayed in the table. PFS in
arm A reached 9.7mo, in arm B 10.1mo (HR 0.92, p¼n.s.). PFS cohort II was 13.0 vs
9.0mo in arm A and B, respectively (HR0.457, p¼ 0.068). PFS in BRAFmutated was
comparable between arm A and B (6.5 vs 6.1mo, HR 1.368, n.s.). Secondary resections
were achieved in 33.3% (arm A) and 12.1% (arm B), R0 in 61.9% vs. 75.0%, respec-
tively. In cohort 1, resections were achieved in 14% vs 0%, in cohort 2 in 75% vs 36.4%.
RFS after resection of metastases was 7.9 vs 4.0 months in arm A and B, respectively
(HR 0.623, p¼n.s.). Treatment related adverse advents grade 3-5 occured in 81.3% and
66.7% in arms A and B, respectively (p¼ 0.1336). Non.haematological AEs grade 3-5
were more frequent in arm A (71.9%) than in arm B (39.4%), p¼ 0.0039. Nevertheless,








ITT, n¼ 96 87.3 60.6 0.0041 4.469 1.614-12.376
Cohort II, n¼ 31 100.0 63.3 0.0105 24.6 1.1778-513.8
Left, n¼ 78 90.6 68.0 0.0210 4.518 1.298-15.718
Right, n¼ 18 70.0 37.5 0.3416 3.889 0.543-27.886
RAS/BRAF wt, n¼ 60 86.0 64.7 0.0806 3.364 0.902-12.549
BRAF mut, n¼ 16 85.7 22.2 0.0406 21.000 1.504-293.25
Conclusions:mFOLFOXIRIþ Panitumumab results in significantly higher ORR com-
pared to FOLFOXIRI. Strong effectivity was observed also in right sided and BRAF
mutated CRC. High secondary resection rates could be achieved. Although toxicity
(treatment related SAEs) was increased, QL reporting was similar in both arms. OS is
still immature, but will be presented first time at the meeting.
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